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ABS TRACT
The antibiotic pipeline is running dry and infectious disease remains a major threat to public health. An
efficient strategy to stay ahead of rapidly adapting pathogens should include approaches that replace,
complement or enhance the effect of both current and novel antimicrobial compounds. In recent years,
a number of innovative approaches to manage disease without the aid of traditional antibiotics and
without eliminating the pathogens directly have emerged. These include disabling pathogen virulence-
factors, increasing host tissue damage control or altering the microbiota to provide colonization resist-
ance, immune resistance or disease tolerance against pathogens. We discuss the therapeutic potential
of these approaches and examine their possible consequences for pathogen evolution. To guarantee a
longer half-life of these alternatives to directly killing pathogens, and to gain a full understanding of their
population-level consequences, we encourage future work to incorporate evolutionary perspectives into
the development of these treatments.
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BEYOND KILLING
The emergence of widespread resistance to antibi-
otics is driving an intense search for alternative
therapeutic approaches against bacterial pathogens
[1, 2]. A major part of this effort focuses on discover-
ing novel antimicrobial drugs [3, 4]. However, the
evolution of drug resistance appears to be inevitable
(despite some interesting exceptions such as the
continued susceptibility of Treponema pallidum [5]
and Streptococcus pyogenes [6] to penicillin), mean-
ing that novel antimicrobial drugs will only offer at
best a temporary solution [7, 8]. The discovery of
novel antimicrobial drugs, while crucial, should ad-
vance alongside approaches that minimize the
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evolutionary potential of pathogens [9–11]. The high
killing potential of current drugs is one of the
strongest sources of selection exerted on patho-
gens, as evidenced by the rapid and consistent evo-
lution of antibiotic resistance [8]. The reason why
antimicrobial drugs lead to the evolution of drug re-
sistance is simply natural selection, which leaves be-
hind the pathogen strains most capable of surviving
the deleterious effects of antimicrobial compounds.
Novel therapeutic approaches should therefore aim
to minimize the impact of this evolutionary re-
sponse, and one way to do so is to control infections
without killing pathogens directly. Here, we review
three promising advances that move beyond direct
killing to reduce disease severity, including: (i) the
targeting of the effectors of pathogenicity rather than
the pathogen itself; (ii) improving tissue damage
control, thereby improving the host’s capacity to tol-
erate pathogens; and (iii) targeting the microbiome
in order to build a natural line of defence against
pathogens. For each approach, we introduce its
mode of action, present key examples, and discuss
putative selection pressures and evolutionary re-
sponses to treatment. Finally, we discuss the applic-
ability of these approaches, and emphasize that it is
imperative to investigate in more detail the longer-
term evolutionary consequences of such treatments.
DISARMING PATHOGEN
VIRULENCE FACTORS
One promising alternative to classic antibiotics is to
focus on strategies reducing pathogen virulence,
which we define in the broadest sense as the degree
of pathology and overall disease symptoms
experienced during infection. Pathogen virulence
can be targeted at least at three levels (Fig. 1)
[12–14], by interfering with: (i) pathogen adhesion,
which is important for host invasion and coloniza-
tion; (ii) quorum sensing, a cell-to-cell signalling sys-
tem used by bacteria to coordinate the secretion of
virulence factors; and (iii) expression and activity of
virulence factors, which are usually secreted pro-
teins or secondary metabolites that act directly or
indirectly to cause tissue dysfunction and/or dam-
age [9, 12]. Approaches belonging to these
categories are called anti-virulence therapies, as they
deprive essential virulence factors from infections
without directly killing the pathogens themselves.
One example of such an anti-virulence drug ap-
proach was recently described in Clostridium difficile
infections, where a synthetic compound called
ebselen was found to be effective in inhibiting two
major virulence-causing toxins (TcdA and TcdB)
[16]. When tested in a mouse model, it was
shown that ebselen reduced the disease severity of
C. difficile infections without affecting the pathogen
load [16]. Another example of pharmacological
approaches targeting virulence factors is the use of
phosphonosulphonates to treat Staphyloccocus aureus
infection. These compounds inhibit the production
of staphyloxanthin, a bacterial anti-oxidant pigment
that normally protects S. aureus from reactive
oxygen species and neutrophil-based killing. When
staphyloxanthin is inhibited, S. aureus becomes vul-
nerable to innate immune resistance mechanisms,
Figure 1. Examples of anti-virulence approaches. (A) In a classical infection, bacteria adhere to host tissue using their flagella and pilli. They then secrete quorum-
sensing molecules (red dots) to communicate with nearby cells in order to coordinate the secretion of harmful virulence factors (green pentagons), such as toxins
and tissue-degrading enzymes. (B)A potent anti-virulence approach is to prevent bacterial adhesion by the administration of hydrophilic compounds (purple layer)
[15]. (C) Interference with bacterial communication, called quorum-quenching has been proposed as another efficient way to control bacterial infections.
Numerous drugs (yellow half-circles) have been shown to either quench the bacterial signals outside the cell or to directly stall signal production within cells
[26], (D)Approaches have also been developed to target the damaging virulence factors (e.g. siderophores, toxins) directly by either suppressing their synthesis or
by inhibiting their actions once secreted [12]
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without interfering with commensal conspecifics [17].
Finally, a recent study successfully targeted the iron-
scavenging capacity of Pseudomonas aeruginosa,
through the administration of gallium, an iron-mimic,
which binds to iron-scavenging siderophores
produced by the pathogen. Gallium disables sidero-
phores outside the cells, thereby preventing iron up-
take and inducing iron-starvation [18]. Although these
examples represent novel approaches to manage in-
fection, it is also worth noting that some antibiotics, in
addition to killing, can also exhibit anti-virulence ef-
fects. For example, both clindamycin and gentamycin
can reduce the toxin production underlying toxic
shock syndrome [19], and azithromycin can reduce
expression of virulence genes in P. aeruginosa [20].
The above examples illustrate that effective anti-
virulence treatments already exist. However, they
also show that the initial idea of disarming patho-
gens without curbing their fitness might often not
hold. For instance, phosphonosulphonates expose
bacteria to host-mediated removal, and gallium in-
duces iron starvation. Hence, the question about the
evolutionary robustness of these therapies, which is
required for their sustainable use in the long-term,
needs closer examination. Theoretical work sug-
gests that the evolution of resistance against anti-
virulence is restricted if disarming a virulence factor
has no fitness consequences for the pathogen [12].
Here, resistant variants might evolve but should not
spread because they enjoy no fitness advantage
compared with the susceptible wild type. Although
it is difficult to imagine that bacteria express traits
that have absolutely no effect on their growth and/or
survival, there are at least a few examples (see the
above-mentioned ebselen therapy, but also [21])
that seem to meet this criterion. Alternatively, it
has been suggested that drug resistance against
anti-virulence treatments should not easily spread
if the therapy targets a virulence factor that is se-
creted and shared between pathogen individuals
[22, 23]. In this scenario resistant mutants might
restore production of the drug-inhibited virulence
factor or produce a modified, more potent, version
of it [18, 24]. However, these mutants should not
spread because the freshly produced virulence fac-
tors are shared among cells and thereby benefit mu-
tant and susceptible wild-type individuals alike. The
above-mentioned gallium therapy falls within that
category, because it targets secreted and publically
shared siderophores. Evolutionary experiments in-
deed revealed no detectable signs of resistance
against gallium, indicating that even drugs reducing
pathogen growth can be evolutionarily robust, if they
target shared virulence factors [18]. In addition to
reducing the potential for resistance to spread, one
could also seek to reduce the probability that resist-
ant mutants arise in the first place. Although
this point is typically considered in antimicrobial
drug design [11], it has particular relevance for
anti-virulence drugs that target secreted virulence
factors outside the cell. The idea is simple: extra-
cellular modes of drug actions should prevent com-
mon resistance mechanisms, such as limitation of
drug entry, increased drug efflux or intra-cellular
drug degradation, from operating [25]. Extra-cellular
quenching of siderophores or quorum-sensing sig-
nals are approaches belonging to this category of
treatments [18, 26].
These considerations suggest that anti-virulence
therapies can be evolutionarily more robust than clas-
sic antibiotic treatments if the virulence factor in ques-
tion: (i) has marginal fitness effects; (ii) is shared
among individuals; (iii) and/or is disabled outside
the cell. If this concept holds true we could not only
use it as a guideline for future drug design, but also
identify the approaches that are less likely to be evo-
lutionarily robust. For instance, the above-described
phosphonosulphonates therapy to treat S. aureus in-
fection [6] does not belong to any of the three
categories, as this therapy reduces pathogen fitness
and targets a private and not a secreted shared viru-
lence factor. Thus, it seems conceivable that resist-
ance in the form of restoration of the defence
against the host’s innate immune system could quite
easily evolve. However, strong conclusions on the evo-
lutionary robustness of anti-virulence therapies are
currently not possible because we simply lack esti-
mates of the strength selection imposed by different
anti-virulence treatments on pathogens. This calls for
studies that actually measure the selection pressures
exerted by the different treatment schemes also taking
into account any possible pleiotropic effects including
undesirable changes in pathogen or host behaviour.
TARGETING TISSUE DAMAGE CONTROL
MECHANISMS TO ENHANCE HOST
TOLERANCE OF INFECTIONS
In this section, we examine therapeutic approaches
that strengthen the host’s ability to control and re-
pair tissue damage. Although host mechanisms of
pathogen elimination such as immune-mediated
clearance are key to defence against pathogens, add-
itional defence mechanisms which prevent, repair
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and limit the extent of tissue damage are also
required to control infections [27]. Tissue damage
control mechanisms are interesting from a thera-
peutic perspective because they enhance the cap-
acity of an infected host to minimize disease
severity, that is, to tolerate the pathogenic effects
of infection [28, 29]. Disease tolerance may be
defined as the host’s ability to maintain health when
faced with increasing pathogen loads [28–30], and
tissue damage control is one way to maintain health
during infection [27]. Prevention or repair of tissue
damage has been shown to confer disease tolerance
of severe sepsis caused by polymicrobial infections
[31], malaria caused by Plasmodium infection [32]
and for co-infections by influenza virus and bacteria
leading to pneumonia [33].
Recently, specific pharmacologic agents have
been developed to specifically target tissue damage
control mechanisms and to confer tolerance of in-
fectious diseases. For example, a low dose regimen
of anthracyclines has been shown to provide a pro-
tective effect during sepsis, preventing multi-organ
dysfunction and damage even though the treatment
does not reduce the bacterial load [34]. This example
of tissue damage control leading to increased dis-
ease tolerance arises because anthracyclines induce
a DNA-damage response that leads to the activation
of autophagy-related pathways and reduction of sys-
temic inflammation, the main cause of multi-organ
dysfunction and damage associated with the patho-
genesis of sepsis [34]. Targeting tissue damage con-
trol mechanisms therapeutically, as demonstrated
as a proof of principle for anthracyclines could there-
fore be a promising alternative or addition to the
widespread use of antibiotics if it can minimize the
severity of infection while helping the host immune
response to clear the infection. In many ways,
treating the symptoms of infection rather than
focusing on killing the root cause is not a new con-
cept. Non-steroidal anti-inflammatory drugs are fre-
quently used for the alleviation of symptoms for
various infectious diseases. By treating the symp-
toms of infection without eliminating pathogens,
these treatments are essentially tolerance-boosting
therapies [9].
One approach to uncover novel therapeutic tar-
gets for tissue damage control is to unravel the
underlying causes for the enormous variation in dis-
ease tolerance that is often observed between spe-
cies or even sub-species in their response to
zoonotic pathogens. For example, bats, mice and
humans are susceptible to infection by the Ebola
virus, but these species have very different disease
outcomes. It has been speculated that bats are es-
pecially capable of tolerating many zoonotic viruses
through a combination of attenuated immunity—
which reduces potential immunopathology—and
the ability to minimize oxidative stress—an adapta-
tion to metabolically costly activities like flight
[35, 36]. The combined result is incomplete viral
clearance and reduced immunopathology, which
has been suggested as a plausible explanation for
bats being such accomplished viral reservoirs, al-
though concrete data to this effect is currently
lacking. One way to compare groups of hosts that
may differ in their ability to limit damage during in-
fection is to obtain health read outs (e.g. survival,
anaemia, immune markers) for increasing pathogen
doses under controlled experimental conditions.
These groups of hosts (e.g. different species as in
the Ebola example, or human patients receiving
damage limitation therapies) may differ in various
parameters of this pathogen dose-host health re-
sponse, including host vigour (the baseline level of
health in the absence of infection), sensitivity to in-
creases in pathogen load (the infection dose at
which host suffer a severe decline in health) the rate
at which host health decreases with increasing
pathogen loads (the slope of the decline in health),
or the severity of infection, which determines how
sick a host can get during infection (Fig. 2). Variation
in each of these parameters may reflect distinct
underlying mechanisms that either promote greater
prevention of damage during infection, or increase
damage repair after the damage has been done [29].
If we were able to identify novel mechanisms of dis-
ease tolerance, we could then seek to develop
therapies that enhance them with drugs that are
likely to be more evolution-proof than conventional
antibiotics.
Finally, it has been recognized that pathogen elim-
ination mechanisms can work together with host
mechanisms that promote tissue damage control
and increase disease tolerance [30, 37, 38]. The idea
is thus to develop therapeutics that strengthen the
interaction between elimination and repair, especially
in cases where pathogen elimination mechanisms fail,
on their own, to reduce the pathogenesis of infectious
diseases. For example, recent studies on mice infected
withListeriamonocytogenes revealed that both the early
immune-driven process leading to pathogen elimin-
ation and mechanisms that maintain host health at
later stages of infection are important hallmarks for
survival [39]. These insights were gained by tracing
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individual health trajectories during infection, con-
structed by plotting time-ordered, individual repeated
measures of pathogen load against health throughout
infection [40, 41]. This novel analytical approach can
be used to monitor the interplay between pathogen
elimination and host repair mechanisms and
their combined effect on infection outcome, thus
illustrating an individual’s infection path towards ei-
ther recovery or death. The Listeria study described
earlier [39] demonstrated that survivors and non-
survivors of infection can assume divergent infection
paths several days prior to death and that these paths
are at least partly genetically determined [39]. This
would suggest that one could predict the likely infec-
tion outcome based on characteristics of the infection
paths at earlier stages of infection. Future studies
should aim at determining the range of physiologically
possible health trajectories associated with different
types and outcomes of infections and at identifying
the key regulatory mechanisms that are responsible
for divergence in infection paths.
Alternatively to sequential dependence illustrated
in [39], mechanisms that eliminate pathogens may
overlap with tissue damage control mechanisms as
illustrated by the immune response to parasitic
worms. These parasites typically do not replicate in
the host and, instead, represent a very different kind
of threat; they typically injure or damage host tissues
in order to enter, migrate or feed. Thus, infection by
these parasites requires that any tissue damage be
rapidly repaired and parasite numbers stay below a
threshold that would compromise host fitness [42,
43]. This dual requirement has led to an immune
response that relies on overlapping pathways to kill
or expel the parasites, and to repair the damage they
cause [44]. Thus the anti-worm effector responses
have likely evolved directly out of wound healing
pathways that confer tissue damage control [42, 43].
Although beneficial for the infected individual, the
population-level consequences for pathogen evolu-
tion and spread of boosting host tolerance by im-
proving tissue damage control have received
relatively little attention [9]. The link between dam-
age control, disease spread and pathogen evolution
becomes intuitive when one recognizes that the abil-
ity of a pathogen to replicate and infect other indi-
viduals is constrained by how much damage it
causes before its host dies (virulence) and how this
level of virulence affect host evolutionary fitness [45].
Limiting tissue damage makes hosts healthier, but
without eliminating pathogens directly potentially
turns these hosts into disease reservoirs or silent
spreaders [36, 46]. Evolutionary and epidemiological
theory suggests that for infections where there is a
strong link between virulence (infection-induced
mortality) and pathogen fitness (the ability to repli-
cate and spread to other hosts), therapies that limit
tissue damage during infection can lead to the evo-
lution of more virulent and also more prevalent in-
fections [9, 47]. This link between virulence and
pathogen fitness is particularly expected for obligate
pathogens, where transmission between hosts is the
main determinant of pathogen fitness. Conversely,
this link is supposedly weaker for facultative patho-
gens, which can grow in non-disease contexts [48]
and tolerance-boosting therapies are therefore ex-
pected to have fewer negative evolutionary conse-
quences in this group of pathogens. Although
these considerations suggest some caution, and
highlight that it is necessary to balance the immedi-
ate benefits of alleviating virulence for individual pa-
tients with the potential longer-term costs for the
population as a whole, the ubiquitous problem of
antibiotic resistance makes it worth investigating if
there are specific clinical scenarios where therapies
Figure 2. When comparing the ability of two different groups of hosts to limit damage during
infection (e.g. a group with or without a damage control therapy), a common approach is to
analyse how host health changes with increasing infection loads for each of the groups of
interest. As pathogen loads increase during infection, hosts will lose health, going from a state
of no symptoms to illness, and in extreme cases even death. In its simplest form, this relation-
ship may be linear [30, 37], and host groups showing steep negative slopes for this reaction
norm suffer a loss in health with increasing loads, while hosts with flat reaction norms are able to
maintain health even as pathogen loads increase, and are therefore relatively tolerant. A poten-
tially more realistic outcome is a non-linear relationship between host health and pathogen
load. Hosts with more efficient damage prevention or repair mechanisms are able to maintain a
higher level of health during infection (blue line) by affecting the sensitivity, slope or severity of
the dose-response curve. The aim of therapies that promote tissue damage control is to flatten
these relationships (by increasing the period before health plunges and/or lowering the slope)
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promoting tissue damage control may be beneficial
at both the individual and population levels.
MANIPULATING COMMENSAL
MICROBIOTA TO REDUCE INFECTION
A host’s health can be greatly impacted by its
microbiome [49]. This realization has spurred mo-
mentum into studying the effects of microbes on ani-
mal and human biology, notably their role in altering
host susceptibility to infection by different pathogens
[49–53]. Bacteria, whether pathogenic or commensal,
have evolved a battery of mechanisms to remove
competitors and colonize their host, including the
release of toxins and phage that directly kill competi-
tors or provocation of host immune responses to
which they are resistant, but their competitors are
susceptible. Amongst pathogens prominent ex-
amples include the release of shiga toxin encoding
phage in shigatoxinagenic Escherichia coli [54], pro-
duction of the toxin pyocyanin by P. aeruginosa [55],
recruitment of neutrophils into the paranasal spaces
byHaemophilus influenza [56] and suicidal invasion of
the gut tissue to provoke inflammation by Salmonella
enterica serovar Typhimurium [57]. These examples
show that there are strong competitive interactions
between the commensal microbiome and pathogens,
which opens the possibility for therapeutic interven-
tions aiming at strengthening the microbiome and
weakening the invasion potential of pathogens [58].
One prominent example of how protective bac-
teria can be used in therapeutic interventions is
the treatment of C. difficile infections in humans.
Briefly, C. difficile colitis occurs following perturb-
ation of the host’s commensal microbiota, most
commonly due to antibiotic treatment of unrelated
infections [59]. A combination of evolved antibiotic
resistance and intrinsic resistance factors such as
spore formation, make that traditional antibiotic
treatment often fails to eradicate C. difficile colitis
[60]. An alternative therapy of ‘faecal transplant’ or
bacteriotherapy, whereby the microbiome of the pa-
tient is repopulated using faecal material from
healthy donors, has recently shown great promise,
with high success rates in curing otherwise recurrent
infections [61, 62]. Furthermore, the ecological basis
of the success of this treatment has been mechan-
istically disentangled using a combination of
sampling of human patients and experiments with
a mouse model [63]. This study has shown that it is
C. difficle’s cogenerClostridium scindens that protects
against C. difficile infection by biosynthesis of
secondary bile acids, which suppress C. difficile
growth [63]. This work offers hope of using precise
alterations to the human microbiota in order to pro-
tect against C. difficile infection.
Bacteriotherapy is not only a feasible defence
against C. difficile infection; similar modifications
of the gut microbiome have been suggested to treat
a range of other infections. Enterococcus faecalis is
a leading cause of hospital-acquired and often sys-
temic infections with an increasing frequency of
multi-drug resistant strains. However, many
E. faecalis strains can also be a constituent of the
normal healthy gut flora. Recent work in a mouse
model of E. faecalis infection has shown that engin-
eering strains of E. faecalis that express bacteriocin
21 encoded on conjugation-defective plasmids can
clear infections of vancomycin resistant E. faecalis
strains [64]. Strikingly, this treatment had no detect-
able effect on the composition of other species in the
microbiota, with the treatment simply resulting in
replacement of the virulent multi-drug resistant
strain with a drug-susceptible commensal [64].
Similarly, it has been suggested that introducing
commensal strains of Staphylococcus epidermidis
could help reduce nasal carriage of drug resistant
S. aureus via competitive exclusion [65]. As an alter-
native to genetic engineering, a novel approach
would be to explore the degree to which natural vari-
ation in protective traits of single microbe species
[58, 66] or whole microbiomes can be engineered
through artificial selection. Experimental evolution
approaches might prove very powerful in generating
protective microbes and microbiomes with specific
effects on disease defence.
These approaches are highly complementary to
anti-virulence and tolerance increasing treatments,
as introducing natural or engineered bacteria to a
patient may be used to block pathogen virulence or
promote tolerance. For instance, Vibrio cholerae’s
virulence is negatively regulated by one of its
quorum sensing molecules, cholera autoinducer
1 (CA-1). Introducing an engineered commensal
E. coli strain that also produces CA-1 has been show
to greatly reduce V. cholerae virulence in a mouse
model, limiting binding of cholera toxin to the intes-
tine by 80% and reducing V. cholera abundance by
69%, ultimately leading to an increase in host sur-
vival of 92% [67]. Specific components of the gut
microbiota have also been shown to modulate dis-
ease tolerance [68]. For example, gut colonization by
E. coli strain O21:H+ confers a survival advantage
against enteric and lung bacterial infections in mice
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without interfering with pathogen load, thus reveal-
ing that this E. coli strain induces host mechanisms
that result in disease tolerance of bacterial infections
[68]. The exact mechanism via which this occurs in-
volves sensing of E. coliO21:H+ triggering the induc-
tion of insulin-like Growth Factor-1, which acts
systemically to alleviate muscle wasting [68]. It is
this tissue damage control mechanism—in this case
stimulated by a modification of the gut microbiota—
that accounts for the survival advantage conferred
by E. coli O21:H+ against bacterial infections.
These examples highlight a great promise in effect-
ive microbiome-control therapies, yet understanding
their evolutionary consequences is vital for assessing
their suitability and sustainability as therapeutic
approaches against infectious diseases. So far the
consequences of alteration of the microbiome for
pathogen evolution and epidemiology have received
little attention [69], and we can therefore only specu-
late about possible evolutionary responses to
microbiome therapy. Because these treatments aim
to strengthen the opponents of the pathogen, they
may create selection for increased expression of the
pathogen’s arsenal of weapons used to clear com-
mensals, potentially increasing their virulence. This
adaptation of ‘fighting back’ is a likely outcome of
pathogen evolution in cases where toxins are the dir-
ect causes of virulence in humans and are required to
clear commensal competitors [69]. In addition to
evolving to fight back against the strengthened
microbiome, pathogens could evolve greater protec-
tion against its competitive effects. A recent experi-
mental evolution study co-culturing S. aureus with
the competitor S. epidermidis has shown that S. aureus
can evolve resistance to the toxins used by
S. epidermidis for competitive exclusion [65]. This study
not only directly demonstrates that pathogens can
evolve in response to the introduction of competitors,
but highlights the utility of experimental evolution
approaches to predict to potential responses to novel
treatments. Additionally, one of the most common
responses of bacteria to resist ecological competition
is to form biofilms, which also greatly increase their
resistance to antibiotics [70], and increases in biofilm
formation could conceivably evolve in response to
microbiome therapy. These considerations empha-
size that, although bacteriotherapy is increasingly
explored as a promising therapeutic approach against
infections that are recalcitrant to traditional antibi-
otics, it is critical that their evolutionary consequences
are elucidated to prevent unwanted repercussions
arising from pathogen evolution.
CONCLUSIONS
Pathogen evolution and the resulting resistance
against treatments present a serious challenge to
public health. Here, we propose three therapeutic
approaches (disarming pathogens, boosting the
host’s damage repair systems and strengthening
the natural microbiome) that move away from direct
pathogen killing to strategies that manage rather than
eradicate infections. These approaches represent a
fundamental conceptual shift in the way we think
about infections, and could potentially be applied to
both acute and chronic infections. Although all
approaches look promising, a number of important
questions remain to be addressed (Box 1). Because
drug resistance evolution involves fundamental bio-
logical processes such as genetic variation and nat-
ural selection, managing these issues will only be
successful if they are systematically addressed within
an evolutionary ecology framework. First, a detailed
mechanistic understanding of how virulence is
mediated, and how hosts mount repair responses
and interact with their microbiome is required. Only
this knowledge will allow us to identify the most ap-
propriate targets for evolutionarily robust and effi-
cient therapies. In addition, interactions between
the three approaches should be better understood.
After all, virulence factors cause tissue damage and
interfere with the microbiome, which opens the pos-
sibility for integrative therapies that simultaneously
weaken the pathogen and strengthen the host.
Box 1: Five outstanding questions
. What are the types and strengths of se-
lection pressures that anti-virulence, tol-
erance and microbiome manipulation
therapies impose on pathogens?
. Which virulence traits should be tar-
geted to minimize selection on
pathogens?
. What are the important components of
host disease tolerance, and how can
they be therapeutically enhanced to sup-
press disease in concert with host
pathogen elimination mechanisms?
. How can the human microbiome be
manipulated/strengthened to efficiently
compete with pathogens?
. How do the three therapeutic
approaches interact, and are there ways
to synergistically combine them?
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Second, a systematic theoretical framework is needed
which examines the evolutionary robustness of the
different approaches. It is important to realize that
whatever therapy is used, it is likely to modify the
within-host environment, and therefore inevitably im-
poses a different selection pressure on pathogens.
Microbial adaptation to environmental changes, such
as those imposed by therapy simply seems unavoid-
able, so it is vital that we investigate the potential
epidemiological and longer-term evolutionary conse-
quences of these new approaches to managing infec-
tions. Clearly, the urgent need for new strategies to
fight infectious disease requires a close collaboration
between scientists from molecular biology, evolution-
ary biology and medicine.
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